Revolutionary Blood Glucose Monitor Enters AI-Powered Clinical Analysis








Glucotrack (NASDAQ: GCTK) has partnered with OneTwo Analytics AB to analyze clinical study data for its Continuous Blood Glucose Monitor (CBGM) using AI-driven analytics. The collaboration aims to evaluate the performance and clinical value of Glucotrack’s innovative CBGM technology.

Unlike traditional monitors that measure glucose in interstitial fluid, Glucotrack’s CBGM is a long-term implantable device that measures glucose directly from blood, providing real-time readings without lag time. The device operates without external components and is designed to offer three years of continuous monitoring.

Through this partnership, OneTwo Analytics will apply their expertise in…

Source link